Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Securities Code: 4577
August 3, 2026

To our shareholders:

Hiroshi Matsumori, President and CEO
Daito Pharmaceutical Co., Ltd.
326 Yokamachi, Toyama City, Toyama Prefecture

Notice of the 84th Annual General Meeting of Shareholders

Daito Pharmaceutical Co., Ltd. (the "Company") hereby announces that its 84th Annual General Meeting of Shareholders of the Company will be held as follows.

In convening this General Meeting of Shareholders, the Company has taken electronic provision measures with respect to information contained in the Reference Documents for the General Meeting of Shareholders and other materials (the "Information Subject to Electronic Provision Measures"). Such information has been posted on the following websites. Shareholders are kindly requested to access either of these websites and review the information.

【The Company's website】

https://www.daitonet.co.jp/ir/agm.html (in Japanese)

【TSE website (Listed Company Search)】

https://www2.jpx.co.jp/tseHpFront/JJK010010Action.do?Show=Show (in Japanese)

(Access the TSE website by using the internet address shown above, enter "Daito" in "Issue name（company name)" or the Company's securities code "4577" in "Code," and click "Search." Then, click "Basic information" and select "Documents for public inspection/PR information." Under "Filed information available for public inspection," click "Click here for access" under "[Notice of General Shareholders Meeting /Informational Materials for a General Shareholders Meeting].")

If you are unable to attend the meeting in person, you can exercise your voting rights in writing (by mail) or by electronically (via the Internet, etc.) in accordance with "Guidance on Exercising Voting Rights" (in Japanese only); so please review the Reference Documents for the General Meeting of Shareholders and exercise your voting rights by no later than 5:20 p.m. on Wednesday, August 26, 2026 (JST).

1. **Date and time:** Thursday, August 27, 2026, at 10:30 a.m. (JST) (Reception commences at 9:30 a.m.)

2. **Venue:** 2F, Multi-purpose Room, Toyama International Conference Center 1-2 Ote-machi, Toyama City, Toyama

3. **Purpose of the Meeting**

Matters to be reported:

1. The Business Report, Consolidated Financial Statements, and the audit reports of Consolidated Financial Statements by the Financial Auditor and the Audit and Supervisory Committee for the 84th Fiscal Year (from June 1, 2025, to May 31, 2026)
2. The Non-consolidated Financial Statements for the 84th Fiscal Year (from June 1, 2025 to May 31, 2026)

Matters to be resolved:

Proposal: Election of Seven Directors (Excluding Directors who are Audit and Supervisory Committee Members)

4. **Matters decided concerning the convocation**

- When you attend the meeting in person, you are kindly requested to present the voting form at the reception desk.
- For this general meeting of shareholders, the Company has delivered paper-based documents stating the items subject to measures for electronic provision to all shareholders, regardless of whether or not they have requested them.

  Among the items subject to measures for electronic provision, in accordance with the provisions of laws and regulations and Article 17 of the Articles of Incorporation of the Company, the following items are not provided in the paper-based documents delivered.

  (1) "Systems for Ensuring the Propriety of Business Activities and the Status of its Implementation" in the Business Report

  (2) The Consolidated Statement of Changes in Equity and the Notes to the Consolidated Financial Statements

  (3) The Non-consolidated Statement of Changes in Equity and the Notes to the Non-consolidated Financial Statements

  Accordingly, the Business Report, Consolidated Financial Statements, and Non-consolidated Financial Statements included in the documents are part of the documents audited by the Financial Auditor in preparing the Accounting Audit Report and by the Audit and Supervisory Committee in preparing the Audit Report.
- If revisions to the items subject to measures for electronic provision arise, a notice of the revisions and the details of the items before and after the revisions will be posted on each of the websites mentioned on page 1.
- If voting rights are exercised in writing (by mail), when the voting form shows neither approval nor disapproval of a proposal, it shall be counted as approval of the proposal.

Reference Documents for the General Meeting of Shareholders

Proposal and Reference Information

Proposal: Election of Seven Board Directors (Excluding Board Directors who are Audit and Supervisory Committee Members)

All five Board Directors (excluding Board Directors who are Audit and Supervisory Committee Members; hereinafter the same shall apply in this proposal) will expire at the conclusion of this meeting. Therefore, to further strengthen the management system and enhance corporate governance, the Company proposes to increase the number of Board Directors from the current five to seven and requests the election of seven Board Directors. The election of each candidate is based on the report of the Nomination and Compensation Advisory Committee.

The candidates for Board Director are as follows:

Candidate No.	Name (Date of birth)	Career summary, and position and responsibility in the Company (Significant concurrent positions outside the Company)	Number of the Company's shares owned
1	 Hiroshi Matsumori (July 24, 1956)	Apr. 1982 Joined Taito Pfizer Co. (currently Pfizer Japan Inc.) Apr. 1994 Product Manager of Antimycotic Agent Group, Medicine Marketing Department Dec. 1996 General Manager of Clinical Development Department,, Clinical Development Division, Research & Development Group (in charge of medicine for infectious disease) May 2000 General Manager of Drug Development Regulatory Affairs Department Mar. 2004 Global Regulatory Leader, Seconded to La Jolla Research Institute, Pfizer Inc., Sep. 2008 Executive Officer, General Manager of Corporate Planning Division of Pfizer Japan Inc. Mar. 2009 Executive Officer, Head of Corporate Affairs Quality Assurance Department and Marketing Supervisor-General Dec. 2009 Director and Executive Officer, Head of the Established Pharmaceutical Business Apr. 2013 Director and Executive Officer, Vice President in charge of Strategy for the Established Pharmaceutical Business in Asia-Pacific Region (retired in December 2013) Dec. 2013 Representative Director, CEO of SBI Biotech Co., Ltd. (retired in September 2014) Oct. 2014 Representative of Matsumori Pharma Consulting Apr. 2016 President and CEO of Teva Pharma Ltd. (currently Teva Takeda Pharma Ltd.) Apr. 2017 President and CEO of Teva Takeda Yakuhin Ltd. Oct. 2021 Representative Director, President and CEO, of Teva Takeda Pharma Ltd. (retired in April 2023) Oct. 2021 Representative Director, President and CEO, of Teva Takeda Yakuhin Ltd. (retired in April 2023) July 2023 Joined the Company Aug. 2023 Director and Executive Vice President, in charge of Business Strategy, and Head of Administrative Division Jan. 2024 Representative Director, Executive Vice President, in charge of Business Strategy, and Head of Administrative Division Aug. 2024 President Jan. 2025 President and CEO (current position)	28,600 shares
	Reason for nomination as candidate Hiroshi Matsumori has extensive experience and knowledge through longstanding participation in research and development operations at pharmaceutical companies and as a senior member of corporate management. The Company proposes to continue his election as a Board Director, as he has made use of this extensive experience and knowledge to appropriately perform his duties as a Board Director of the Company, including supervising the decision-making and business execution of the Company's overall management, and has contributed to the enhancement of the Company's corporate value.		

Candidate No.	Name (Date of birth)	Career summary, and position and responsibility in the Company (Significant concurrent positions outside the Company)	Number of the Company's shares owned
2	 Kazushige Hizume (February 25, 1962)	Apr. 1985 Joined the Company (former Daito Trading Co., Ltd.) June 2001 Manager of API Sales Department, API Business Division June 2006 General Manager of Formulation Department, Pharmaceutical Business Division, and Deputy General Manager of API Sales Department, API Business Division Apr. 2009 General Manager of Contract Promotion Department, Pharmaceutical Business Division June 2010 General Manager of API Sales Department, API Business Division June 2014 General Manager of Prescription Medicine Department, Pharmaceutical Business Division Aug. 2016 Executive Officer, Deputy Head of Pharmaceutical Business Division and General Manager of Prescription Medicine Department Aug. 2018 Director and Executive Officer, Head of Sales and General Manager of Pharmaceutical Business Division June 2022 Director and Senior Executive Officer, Head of Sales and General Manager of Pharmaceutical Business Division Aug. 2025 Director and Senior Executive Officer, Head of Sales, General Manager of Pharmaceutical Business Division, and Head of Tokyo Branch (current position) [Significant concurrent positions outside the Company] Vice Chairman of Daito Pharmaceutical (China) Co., Ltd.	45,336 shares
	Reason for nomination as candidate Kazushige Hizume has extensive experience and wide-ranging expertise from his many years of sales activities in the Company's API and pharmaceutical business divisions. The Company proposes to continue his election as Director, as he has appropriately performed his duties as a Director of the Company and has contributed to the enhancement of the Company's enterprise value.		

<table>
<tr><th>Candidate No.</th><th>Name
(Date of birth)</th><th colspan="2">Career summary, and position and responsibility in the Company
(Significant concurrent positions outside the Company)</th><th>Number of the Company's shares owned</th></tr>
<tr><td rowspan="2">3</td><td>
Toru Ishida
(December 14, 1960)</td><td>Apr. 1985
Apr. 2008

Apr. 2010

Apr. 2012

July 2013
Apr. 2015

Apr. 2018

Nov. 2022
Sep. 2023
Jan. 2024

June 2024

Aug. 2024

Aug. 2025

June 2026</td><td>Joined Takeda Pharmaceutical Company Limited
General Manager of Chemical Development Laboratories, CMC Research Center, Pharmaceutical Production Division
General Manager of Production Control Department, Pharmaceutical Production Division
General Manager of Production Planning Department, Pharmaceutical Production Division
Head of Hikari Plant, Pharmaceutical Production Division
Head of Hikari Plant, Global Manufacturing and Supply Japan and Asia (retired in March 2018)
Representative Director and President of Takeda Healthcare Products Co., Ltd. (currently Alinamin Pharma Tech Co., Ltd.) (retired in October 2022)
Joined the Company
Executive Officer, Deputy Head of Production Division
Executive Officer, Head of Production Division and General Manager of Environmental Safety Department
Executive Officer, Head of Production Division, General Manager of Drug Product Production Department, and General Manager of Environmental Safety Department
Director, Executive Officer, Head of Production Division, General Manager of Drug Product Production Department, and General Manager of Environmental Safety Department
Director and Senior Executive Officer, Head of Production Division, General Manager of Drug Product Production Department, and General Manager of Environmental Safety Department
Board Director and Senior Executive Officer, Head of Production Division, and General Manager of Environmental Safety Department (current position)</td><td>0 shares</td></tr>
<tr><td colspan="4">Reason for nomination as candidate
Toru Ishida has extensive experience and wide-ranging expertise through his extensive experience in R&D and manufacturing operations in the pharmaceutical industry, as well as his experience in corporate management. The Company proposes to continue his election as Board Director, as he has made use of this extensive experience and knowledge to appropriately perform his duties as a Board Director of the Company and has contributed to the enhancement of the Company's corporate value.</td></tr>
</table>

Candidate No.	Name (Date of birth)	Career summary, and position and responsibility in the Company (Significant concurrent positions outside the Company)	Number of the Company's shares owned
4	 [New election] Yutaka Kuwashima (February 8, 1964)	Apr. 1986 Joined Daito Trading Co., Ltd. (currently Daito Pharmaceutical Co., Ltd.) Aug. 2016 Executive Officer, Head of Corporate Planning Office, the Company Aug. 2017 Executive Officer, Head of API Business, the Company Aug. 2018 Director, Daiwa Pharmaceutical Co., Ltd. (currently Daito Pharmaceutical Co., Ltd.) Director, Cheer Fine Pharmaceutical Co., Ltd. June 2019 Director, Feldsenf Pharma Co., Ltd. Aug. 2021 Senior Corporate Officer, Head of API Business and General Manager of Tokyo Branch, the Company Aug. 2025 Senior Corporate Officer, Head of Quality and Regulatory Affairs, the Company (current position) Oct. 2025 Director, Daito Pharmaceutical (China) Co., Ltd. (current position) [Significant concurrent positions outside the Company] Director, Daito Pharmaceutical (China) Co., Ltd. Director, Feldsenf Pharma Co., Ltd.	171,098 shares
	Reason for nomination as candidate Yutaka Kuwashima has engaged in a wide range of fields at the Company, including production management, sales, and corporate planning, and possesses extensive experience and a proven track record. He has played a core role in each field and has contributed to the promotion of the Company's business. Currently, as Senior Corporate Officer and Head of Quality and Regulatory Affairs Division, he oversees the quality department and contributes to the strengthening of the Company's quality control system. The Company proposes his election as Director in the expectation that his extensive experience and expertise will contribute to the Company's sustainable growth and enhancement of corporate value.		

<table>
<tr><th>Candidate No.</th><th>Name
(Date of birth)</th><th>Career summary, and position and responsibility in the Company
(Significant concurrent positions outside the Company)</th><th>Number of the Company's shares owned</th></tr>
<tr><td rowspan="2">5</td><td>
[New election]
Kenji Otsuga
(November 5, 1988)</td><td>Apr. 2012 Joined The Bank of Tokyo-Mitsubishi UFJ, Ltd. (currently MUFG Bank, Ltd.)
Oct. 2018 Assistant Vice President, Asian Corporate Banking (currently Japanese Corporate Banking (East)), MUFG Union Bank, N.A.
Aug. 2021 Manager, Human Resources Division, MUFG Bank, Ltd. (Sponsored Student at Harvard Business School, USA)
June 2023 Joined Daiwa Pharmaceutical Co., Ltd. (currently Daito Pharmaceutical Co., Ltd.)
Jan. 2024 Executive Officer, responsible for Corporate Planning and the President's Office, the company
Aug. 2024 Joined the Company
Sep. 2024 CFO (Chief Financial Officer), the Company
Aug. 2025 Executive Officer and CFO (Chief Financial Officer), the Company (current position)
Aug. 2025 Auditor, Daito Pharmaceutical (China) Co., Ltd. (current position)
[Significant concurrent positions outside the Company]
Auditor, Daito Pharmaceutical (China) Co., Ltd.</td><td>60,242 shares</td></tr>
<tr><td colspan="3">Reason for nomination as candidate
Kenji Otsuga has played a central role in formulating and implementing the medium-term management plan "DTP2027" and as CFO, has demonstrated strong leadership in advancing the Company's financial and capital strategies, investor and shareholder relations activities, and digital transformation initiatives. He also plays a leading role in the absorption-type merger of Daiwa Pharmaceutical, the restructuring of the China business, and the promotion of "The Novel Consortium Initiative" aimed at integrating generic drug items. He currently contributes to the Company's management as an Executive Officer, and the Company proposes his election as a new Director to leverage this experience and knowledge in the Company's management.</td></tr>
</table>

<table>
<tr><th>Candidate No.</th><th>Name
(Date of birth)</th><th>Career summary, and position and responsibility in the Company
(Significant concurrent positions outside the Company)</th><th>Number of the Company's shares owned</th></tr>
<tr><td rowspan="2">6</td><td>
Kimiko Komatsu
(June 20, 1958)</td><td>Apr. 1980 Joined Daido Hospital, Kojunkai Social Medical Corporation
Aug. 1996 Joined Hokuriku Health Service Association
Oct. 2010 Counselor for occupational health and Promoter for mental health measures of Toyama Occupational Health Support Center (current position)
Dec. 2020 Representative of Mind Plus Toyama (current position)
Aug. 2022 Outside Board Director of the Company (current position)
[Significant concurrent positions outside the Company]
Representative of Mind Plus Toyama</td><td>0 shares</td></tr>
<tr><td colspan="3">Reason for nomination as candidate as outside Board Director and outline of expected roles
Although Kimiko Komatsu has never been involved in the management of a company, the Company expects her to continue to contribute to the enhancement of the Company's corporate value from a professional and objective perspective, particularly with respect to employee labor issues, comprehensive mental health measures, and building a better workplace environment, utilizing her extensive experience and knowledge as a licensed industrial counselor and certified psychotherapist. The Company therefore proposes her as a candidate for outside Board Director.</td></tr>
</table>

<table>
<tr><th>Candidate No.</th><th>Name
(Date of birth)</th><th colspan="2">Career summary, and position and responsibility in the Company
(Significant concurrent positions outside the Company)</th><th>Number of the Company’s shares owned</th></tr>
<tr><td rowspan="11">7</td><td rowspan="10">
[New election]
Hiroko Kusano
(September 1, 1960)</td><td>Apr. 1983</td><td>Joined Taito Pfizer Co. (currently Pfizer Japan Inc.)</td><td rowspan="10">0 shares</td></tr>
<tr><td>Mar. 2005</td><td>Director of Cardiovascular Sales, West Japan, Pfizer Japan Inc.</td></tr>
<tr><td>May 2006</td><td>Director of Planning and Promotion, President's Office, Pfizer Japan Inc.</td></tr>
<tr><td>Dec. 2008</td><td>Branch Manager, West Tokyo, Pfizer Japan Inc.</td></tr>
<tr><td>Dec. 2013</td><td>Branch Manager, IM Tohoku, Pfizer Japan Inc.</td></tr>
<tr><td>Apr. 2018</td><td>Advisor, Vital-Net Co., Ltd.</td></tr>
<tr><td>June 2018</td><td>President and Representative Director, Lead Specialties Co., Ltd.</td></tr>
<tr><td>July 2018</td><td>Executive Officer, Deputy Head of Sales and Head of Specialty Care Department and Head of Women's Empowerment Promotion, Vital-Net Co., Ltd.</td></tr>
<tr><td>June 2021</td><td>President and Representative Director, Ayumi Pharmaceutical Corporation</td></tr>
<tr><td>June 2024</td><td>Retired from the same company</td></tr>
<tr><td colspan="4">Reason for nomination as candidate as outside Board Director and outline of expected roles
Hiroko Kusano has extensive experience and distinguished insight, having engaged in sales, marketing, distribution, and management in the pharmaceutical industry for many years, serving in key positions such as branch manager at a foreign-affiliated pharmaceutical company, as well as being involved in corporate management as an executive officer of a pharmaceutical wholesaler and as President and Representative Director of a specialty pharma company. The Company expects her to contribute to the Company’s sustainable growth and the strengthening of corporate governance from an independent standpoint, utilizing her deep knowledge of the entire pharmaceutical supply chain and her management experience, and therefore proposes her as a candidate for outside Board Director.</td></tr>
</table>

Notes:
1. The number of the Company’s shares held by each candidate is as of the end of the fiscal year under review (May 31, 2026).
2. There is no special interest between any of the candidates and the Company.
3. Kimiko Komatsu and Hiroko Kusano are candidates for outside Board Director.
4. Policies and Procedures for Nominating Candidates for Board Directors

   In determining each candidate, the Company considers candidates who can demonstrate strength in the management of each business field in a wide range of business areas, and who possess excellent character, knowledge, and high ethical standards, with due consideration given to the balance between the candidates’ suitability for management and administration.

   In order to enhance corporate governance by strengthening the fairness, transparency, and objectivity of procedures related to determining candidates for Board Directors, etc., the Nomination and Compensation Advisory Committee was established as an advisory body to the Board of Directors, and the Board of Directors respects the recommendations and proposals made by the Nomination and Compensation Advisory Committee to the maximum extent possible when determining candidates.

   The Nomination and Compensation Advisory Committee, upon receiving a consultation from the Board of Directors and chaired by an independent outside Board Director, evaluates and considers candidates for Board Directors based on an appropriate assessment of the Company's performance, etc., in accordance with fair and transparent procedures, and reports the results to the Board of Directors, which then makes the final decision.
5. Opinion of the Audit and Supervisory Committee

   The election of Board Directors (excluding Board Directors who are Audit and Supervisory Committee Members) was based on the Nomination and Compensation Advisory Committee, chaired by an outside Board Director who is an Audit and Supervisory Committee Member, evaluating the candidates' qualifications, etc., based on an appropriate assessment of the Company's performance, etc. Therefore, the Audit and Supervisory Committee has determined that there are no special matters that require a statement of opinion at the General Meeting of Shareholders as provided for in the Companies Act.
6. Outline of Directors and Officers Liability Insurance Agreement

   The Company has entered into a Directors and Officers Liability Insurance Agreement with an insurance company as provided for in Article 430-3, paragraph (1) of the Companies Act, with the Board Directors as insured, and plans to renew and continue such agreement. If each candidate is elected, each of them will be the insured under the said agreement. The outline of such agreement is that, under the said agreement, the insurance company covers losses that may arise from the insured’s assumption of liability incurred in the course of the performance of duties as an officer or a person at a certain position, or receipt of claims pertaining to the pursuit of such liability.

   The agreement does not cover the payment of claims in the event of liability for damages that may arise from an officer’s illegal act or in the event that the Company pursues liability for damages against the officer, and also sets a limit on the amount of compensation to be paid, in order to ensure that the officer’s performance of his or her duties is not impaired.

7. Limited liability agreements with outside Board Director
   The Company has entered into an agreement with Kimiko Komatsu to limit her liability for damages under Article 423, paragraph (1) of the Companies Act as provided for in Article 427, paragraph (1) of the said Act, in order to enable her to fully perform her expected roles, and will plan to renew such agreement if her reelection is approved. The Company also plans to enter into the same agreement with Hiroko Kusano if her election is approved. The maximum amount of liability for damages under the said agreement is the amount stipulated in Article 425, paragraph (1) of the Companies Act.
8. Kimiko Komatsu satisfies the requirements for an independent officer as provided for by the Tokyo Stock Exchange. The Company appointed Kimiko Komatsu as an independent officer, and notified the said exchange of such appointment. Provided she is re-elected as proposed, she will continue her service for the Company as an independent officer.
9. Kimiko Komatsu is currently an outside Board Director of the Company. Upon the conclusion of this meeting, Kimiko Komatsu will have served four years since her appointment.
10. If Hiroko Kusano is elected in this proposal, the Company plans to designate her as an independent officer as provided for by the Tokyo Stock Exchange and notify the said exchange of such designation.

[Reference] Skills Matrix of Board Directors and Audit and Supervisory Committee Members

If the proposal is approved as proposed, the composition of the Company's Board Directors and Audit and Supervisory Committee Members and their main areas of knowledge and experience will be as follows.

Name	Audit and Supervisory Committee Members	Outside	Independent officers	Corporate management	Industry insight	Finance, accounting, and capital market	International experience
Hiroshi Matsumori				○	○		○
Kazushige Hizume					○		
Toru Ishida				○	○		○
Yutaka Kuwashima					○		
Kenji Otsuga				○		○	○
Kimiko Komatsu		○	○				
Hiroko Kusano		○	○	○	○		
Ichizo Yamamoto	○	○	○				
Atsushi Saino	○	○	○	○	○		
Minori Uchida	○	○	○			○	○

Name	Legal, compliance & risk management	Human capital development and labor relations	Marketing and sales	Technology and R&D	Production	Quality assurance
Hiroshi Matsumori		○	○	○		○
Kazushige Hizume			○			
Toru Ishida	○			○	○	○
Yutaka Kuwashima			○		○	○
Kenji Otsuga			○			
Kimiko Komatsu		○				
Hiroko Kusano		○	○			
Ichizo Yamamoto	○					
Atsushi Saino						
Minori Uchida		○				

Note: The above does not cover all of the knowledge and experience possessed by each person.